Mostrando 10 resultados de: 11
Filtros aplicados
Publisher
Pharmacogenomics Journal(3)
Pharmacogenomics(2)
Drug Metabolism and Personalized Therapy(1)
Expert Opinion on Drug Metabolism and Toxicology(1)
Expert Review of Clinical Pharmacology(1)
An update on HLA alleles associated with adverse drug reactions
ReviewAbstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hPalabras claves:abacavir, adverse drug reactions, Allopurinol, carbamazepine, human leukocyte antigen (HLA), hypersensitivity syndrome, pharmacogenetics, Stevens-Johnson syndromeAutores:Adrián LLerena, Fricke-Galindo I., López-López M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCarbamazepine adverse drug reactions
ReviewAbstract: Introduction: Carbamazepine (CBZ) is used for the treatment of epilepsy and other neurological and pPalabras claves:adverse drug reactions, carbamazepine, Hepatotoxicity, Hypersensitivity, hyponatremia, Stevens-Johnson syndrome, Teratogenesis, toxic epidermal necrolysisAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic variation of CYP2C19 alleles, 'pbkp_redicted' phenotypes and 'measured' metabolic phenotypes across world populations
ReviewAbstract: The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and CYP2C19 metaPalabras claves:Autores:Adrián LLerena, Céspedes-Garro C., de Andrés F., Delgado A., Fricke-Galindo I., López-López M., Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F.Fuentes:scopusPharmacogenetics of adverse reactions to antiepileptic drugs
OtherAbstract: Introduction: Adverse drug reactions (ADRs) are a major public health concern and a leading cause ofPalabras claves:ABCC2, adverse drug reactions, Antiepileptic drugs, CYP2C9, human leukocyte antigen (HLA), pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusWorldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes
ReviewAbstract: Introduction: Notably differences in CYP2C9 allele frequencies among worldwide populations have beenPalabras claves:CYP2C9, ethnicity, Genotype, PhenotypeAutores:Adrián LLerena, Céspedes-Garro C., de Andrés F., Fricke-Galindo I., Humberto Fariñas, López-López M., Naranjo M.E.G., Penãs-Lledó E.M., Rodrigues-Soares F.Fuentes:scopusRelevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
ArticleAbstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCPalabras claves:ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus